prikaz prve stranice dokumenta HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
  Preuzmi
PDF 668.46 KB
Znanstveni rad - Pregledni rad
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
International Journal of Molecular Sciences, 24 (2023), 9; 8206. https://doi.org/10.3390/ijms24098206
Popović, Marina; Silovski, Tajana; Križić, Marija; Dedić Plavetić, Natalija

Citirajte ovaj rad

Popović, M., Silovski, T., Križić, M. i Dedić Plavetić, N. (2023). HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?. International Journal of Molecular Sciences, 24. (9). doi: 10.3390/ijms24098206

Popović, Marina, et al. "HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?." International Journal of Molecular Sciences, vol. 24, br. 9, 2023. https://doi.org/10.3390/ijms24098206

Popović, Marina, Tajana Silovski, Marija Križić i Natalija Dedić Plavetić. "HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?." International Journal of Molecular Sciences 24, br. 9 (2023). https://doi.org/10.3390/ijms24098206

Popović, M., et al. (2023) 'HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?', International Journal of Molecular Sciences, 24(9). doi: 10.3390/ijms24098206

Popović M, Silovski T, Križić M, Dedić Plavetić N. HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?. International Journal of Molecular Sciences [Internet]. 04.05.2023. [pristupljeno 18.10.2024.];24(9). doi: 10.3390/ijms24098206

M. Popović, T. Silovski, M. Križić i N. Dedić Plavetić, "HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?", International Journal of Molecular Sciences, vol. 24, br. 9, Svibanj 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:211367. [Citirano: 18.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:211367
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
AutorMarina Popović
AutorTajana Silovski
AutorMarija Križić
AutorNatalija Dedić Plavetić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PATOFIZIOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Patofiziologija
Sažetak (engleski)
Despite the great progress made in the understanding of the biological behavior of certain types of invasive breast cancer, there is still no single histological or molecular classification that encompasses such diversity and accurately predicts the clinical course of distinct breast cancer subtypes. The long-lasting classification of breast cancer as HER2-positive vs. HER2-negative has recently come into question with the discovery of new antibody drug conjugates (ADC), which are proven to be remarkably efficient in treating HER2-low breast cancer. The HER2-low paradigm has challenged the traditional understanding of HER2 overexpression and emphasized the need for more robust HER2 testing in order to encompass HER2 intratumoral heterogeneity and spatial distribution more accurately. It is yet to be seen if low HER2 will remain merely a marker of HER2-equipped tumors targetable with ADCs or if distinctive molecular and phenotypic groups within HER2-low tumors will eventually be discerned.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaInternational Journal of Molecular Sciences
Brojčani podacivol. 24, br. 9, 8206
e-ISSN1422-0067
DOIhttps://doi.org/10.3390/ijms24098206
URN:NBNurn:nbn:hr:105:211367
Datum objave publikacije2023-05-04
URL dokumentahttps://www.mdpi.com/1422-0067/24/9/8206
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-11-02 08:56:05